SLDB
NASDAQSolid Biosciences Inc.
Solid Biosciences Inc. (SLDB) is a Biotechnology: Biological Products (No Diagnostic Substances) company listed on NASDAQ. In the last 30 days Quantisnow tracked 7 wire items for SLDB, including 3 press releases and news items, 3 insider trades and 1 analyst rating. The most recent was published Oct 26, 2026.
Price$6.37+0.19 (+3.07%)
01:30 PM04:45 PM
News · 26 weeks29+200%
2026-05-032026-10-25
Mix1790d
- Other7(41%)
- SEC Filings4(24%)
- Analyst3(18%)
- Insider3(18%)
Latest news
25 items- INSIDERSEC Form 4 filed by Solid Biosciences Inc.4 - Solid Biosciences Inc. (0001707502) (Issuer)
- PRSolid Biosciences Announces European Commission Orphan Designation for SGT-212 and Continued Progress in the FALCON Trial in Friedreich’s Ataxia- Obtaining Orphan designation from the European Commission reflects Solid’s commitment to the global development of SGT-212 for individuals living with Friedreich’s ataxia - - SGT-212 is a first-in-class dual route FA gene therapy designed to combine direct, MRI-guided delivery to the dentate nuclei with systemic delivery to reach cardiac and other systemic tissues - - Five participants have been dosed in the ongoing Phase 1b FALCON clinical trial and SGT-212 has been well tolerated as of October 5, 2026 - - Solid expects to report initial FALCON clinical data in Q1 2027 - CHARLESTOWN, Mass., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ:SLDB) (the "Company" or "Sol
- INSIDERSEC Form 4 filed by Solid Biosciences Inc.4 - Solid Biosciences Inc. (0001707502) (Issuer)
- PRSolid Biosciences to Present Research Across Gene Therapy Development, Delivery and Manufacturing at ESGCT 2026CHARLESTOWN, Mass., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ:SLDB) (the "Company" or "Solid"), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that seven abstracts have been accepted for poster presentation at the 33rd European Society of Gene & Cell Therapy (ESGCT) Annual Congress, taking place October 27-30, 2026, in Hamburg, Germany. The accepted abstracts span multiple areas of gene therapy research, including therapeutic design, next-generation delivery technologies, capsid engineering and manufacturing. The presentations include research supporting SGT-003, Solid's investigational Duchenne
- ANALYSTUBS initiated coverage on Solid Biosciences with a new price targetUBS initiated coverage of Solid Biosciences with a rating of Buy and set a new price target of $20.00
- INSIDERSEC Form 4 filed by Solid Biosciences Inc.4 - Solid Biosciences Inc. (0001707502) (Issuer)
- PRSolid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)CHARLESTOWN, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ:SLDB) (the "Company"), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced a grant of 8,150 restricted stock units ("RSUs") to one newly hired employee. The RSUs vest in four equal installments on each one-year anniversary of the grant date until the fourth anniversary of the grant date. Vesting of the equity awards is subject to the applicable employee’s continued service with the Company through each applicable vesting date. This grant was made pursuant to the Company’s 2024 Inducement Stock Incentive Plan and was made as an inducement
- ANALYSTRBC Capital Mkts initiated coverage on Solid Biosciences with a new price targetRBC Capital Mkts initiated coverage of Solid Biosciences with a rating of Outperform and set a new price target of $18.00
- PRSolid Biosciences to Participate at Upcoming Investor ConferencesCHARLESTOWN, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ:SLDB) (the "Company" or "Solid"), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced participation in the following investor conferences: 2026 Cantor Global Healthcare ConferenceBo Cumbo, President and CEO, and Gabriel Books, M.D., Chief Medical Officer, will participate in a fireside chat on Wednesday, September 9, 2026, at 3:55 p.m. ET. A live webcast of the presentation will be available by clicking here. 2026 Citi Biopharma Back to School ConferenceMr. Cumbo and Dr. Brooks will participate in a fireside chat on Thursday, September 1
- ANALYSTTruist resumed coverage on Solid Biosciences with a new price targetTruist resumed coverage of Solid Biosciences with a rating of Buy and set a new price target of $20.00
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Solid Biosciences Inc.SCHEDULE 13D/A - Solid Biosciences Inc. (0001707502) (Subject)
- SECSEC Form 8-K filed by Solid Biosciences Inc.8-K - Solid Biosciences Inc. (0001707502) (Filer)
- SECSEC Form 424B5 filed by Solid Biosciences Inc.424B5 - Solid Biosciences Inc. (0001707502) (Filer)
- SECSEC Form S-3ASR filed by Solid Biosciences Inc.S-3ASR - Solid Biosciences Inc. (0001707502) (Filer)
- PRSolid Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Updates- Duchenne (SGT-003): SGT-003 has been generally well tolerated in the Phase 1/2 INSPIRE DUCHENNE clinical trial, with 53 participants dosed as of August 4, 2026 - - Solid expects to meet with the FDA in late Q4 2026 to discuss the SGT-003 data package and to seek guidance on a potential accelerated approval pathway for SGT-003 - - Initiation of dosing in the Phase 3 IMPACT DUCHENNE placebo-controlled, randomized, double-blind clinical trial commenced in Q2 2026 - - Friedreich’s Ataxia (SGT-212): Continued participant screening and enrollment is underway in the Phase 1b FALCON clinical trial; SGT-212 has been well tolerated in the two participants dosed as of August 4, 2026 - - Capital P
- SECSEC Form 10-Q filed by Solid Biosciences Inc.10-Q - Solid Biosciences Inc. (0001707502) (Filer)
- SECSEC Form SCHEDULE 13G filed by Solid Biosciences Inc.SCHEDULE 13G - Solid Biosciences Inc. (0001707502) (Subject)
- INSIDERDirector Smith Ian F converted options into 3,440 shares, increasing direct ownership by 3% to 138,145 units (SEC Form 4)4 - Solid Biosciences Inc. (0001707502) (Issuer)
- INSIDERNew insider Ra Capital Management, L.P. claimed ownership of 12,036,126 shares (SEC Form 3)3 - Solid Biosciences Inc. (0001707502) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Solid Biosciences Inc.SCHEDULE 13D/A - Solid Biosciences Inc. (0001707502) (Subject)
- INSIDERSEC Form 4 filed by Director Stone Adam Leo4 - Solid Biosciences Inc. (0001707502) (Issuer)
- SECSolid Biosciences Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Solid Biosciences Inc. (0001707502) (Filer)
- SECSEC Form 424B7 filed by Solid Biosciences Inc.424B7 - Solid Biosciences Inc. (0001707502) (Filer)
- PRSolid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)CHARLESTOWN, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ:SLDB) (the "Company"), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced a grant of 6,580 restricted stock units ("RSUs") to one newly hired employee. The RSUs vest in four equal installments on each one-year anniversary of the grant date until the fourth anniversary of the grant date. Vesting of the equity awards is subject to the applicable employee's continued service with the Company through each applicable vesting date. This grant was made pursuant to the Company's 2024 Inducement Stock Incentive Plan and was made as an inducem
- PRSolid Biosciences to Participate at Upcoming Investor ConferencesCHARLESTOWN, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ:SLDB) (the "Company" or "Solid"), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced participation in the following investor conferences: Jefferies Global Healthcare ConferenceBo Cumbo, President and CEO, will be presenting on Wednesday, June 3, 2026, at 7:35 a.m. ET.A live webcast of the presentation will be available on the Events page of the Investors section of the Company website or by clicking here. The webcast replay will be archived for 90 days on the Events page. Goldman Sachs 47th Annual Global Healthcare ConferenceMr. Cumbo wi
SLDB FAQ
8 questionsWhat does Solid Biosciences Inc. do?
Solid Biosciences Inc., a life science company, engages in developing therapies for duchenne muscular dystrophy (DMD) in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophin protein expression in patients' muscles. Its portfolio also comprises Anti-LTBP4, a complementary disease modifying program that identifies and develops a monoclonal antibody intended to reduce fibrosis and inflammation by targeting and stabilizing the LTBP4 protein. In addition, the company engages in...What is the latest news on SLDB?
In the last 30 days Quantisnow tracked 7 wire items for SLDB: 3 press releases and news items, 3 insider trades and 1 analyst rating. The most recent was published on October 26, 2026.Where does SLDB stock trade?
Solid Biosciences Inc. (SLDB) is listed on NASDAQ.What sector and industry is SLDB in?
Solid Biosciences Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Solid Biosciences Inc. go public?
Solid Biosciences Inc. (SLDB) completed its IPO in 2018.What are analysts saying about SLDB?
Solid Biosciences Inc. has had 8 recent analyst actions on file. The most recent action was from UBS: Buy with a $2000.00 price target on 2026-10-15. Recent price targets range from $1400.00 to $2600.00.What companies are similar to SLDB?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), MRNA (Moderna Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.). Compare SLDB side-by-side with any of them on Quantisnow.How can I track SLDB on Quantisnow?
Quantisnow aggregates Solid Biosciences Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow SLDB to receive live email and push alerts on every new disclosure.